Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials

Pujol, J.L.; Jp, Daurès

doi:10.1200/jco.2005.23.16_suppl.7213

Cited by 10 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy is generally indicated for patients with advanced NSCLC because the results of many large, randomized phase III clinical trials have established that modern chemotherapies offer superior survival and symptom palliation than best supportive care [2]. Specifically, platinum-based chemotherapy has been the worldwide standard based on the single-agent activity of platinum agents as well as meta-analyses suggesting superiority over nonplatinum-based therapy [3,4]. For patients with unresectable stage III disease, a combination of platinum-based chemotherapy and radiotherapy is recommended, whereas in stage IV disease, chemotherapy alone is warranted [3].…”

Section: Introductionmentioning

confidence: 99%

Optimizing First-Line Treatment Options for Patients with Advanced NSCLC

Wakelee

Belani

2005

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to: 1. Explain the clinical implications of large randomized trials evaluating chemotherapy combinations for patients with advanced NSCLC. 2. Summarize the activity and toxicity of current chemotherapy regimens for the first-line treatment of advanced NSCLC. 3. Describe regimens that have quality-of-life benefits in the treatment of NSCLC. 4. Identify potential future standards of care for advanced disease based on recent research findings evaluating novel targeted agents.Correspondence: Chandra P. Abstract CME CME Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com This material is protected by U.S.

show abstract

Section: Introductionmentioning

confidence: 99%

Optimizing First-Line Treatment Options for Patients with Advanced NSCLC

Wakelee

Belani

2005

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Specifically, platinum-based chemotherapy has been the worldwide standard based on the single-agent activity of platinum agents as well as meta-analyses suggesting superiority over non-platinum-based therapy [25,26]. A meta-analysis based on individual data from 3033 patients from 22 trials demonstrated a statistically significant benefit of combining chemotherapy with radiation for these patients.…”

Section: Combined Chemotherapy With Radiotherapy In Locally-advanced mentioning

confidence: 98%

The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience

Méry

Guy

Swalduz

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…The incidence of treatment-related adverse events associated with platinum based chemotherapy has been a key concern since their inception in clinical practice. Retrospective analysis of data from 37 clinical trials attributed an increase in the incidence of nephrotoxicity, hematological toxicity and gastrointestinal adverse events to treatment with platinum based chemotherapy (12). Similarly, chemoradiation therapy indicated for stage III disease in lung cancer has been found to result in significant morbidity (13).…”

Section: Introductionmentioning

confidence: 99%

Immune checkpoint pathways in non-small cell lung cancer

et al. 2018

View full text Add to dashboard Cite

Immunotherapy has evolved at a phenomenal pace in cancer therapeutics. This has primarily been fueled by the much perceived necessity to procure an alternative to current standard of care chemotherapy agents, owing to several concerns such as treatment-related toxicity and poor long-term survival associated with the same. The knowledge of various mechanisms involved in regulation of immune response to cancer cells has served a fundamental role in identifying key molecules through which immune cell activity may be modulated. This in-turn led to the development of immune-checkpoint inhibitors. Presently, lung cancer is among the most enthusiastically investigated targets for treatment with immune-checkpoint inhibitors. Encouraging results with initial trials have now translated to attempts directed at further enhancement of outcomes through various strategies. Herein, we shall present a critical assessment of data from pivotal trials that led to the Food and Drug Administration (FDA) approval of various immune-checkpoint inhibitors and also discuss novel strategies that may potentially yield outcomes superior to standard of care chemotherapy in patients diagnosed with advanced non-small cell lung cancer (NSCLC).

show abstract

Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials

Cited by 10 publications

References 0 publications

Optimizing First-Line Treatment Options for Patients with Advanced NSCLC

Optimizing First-Line Treatment Options for Patients with Advanced NSCLC

The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience

Immune checkpoint pathways in non-small cell lung cancer

Contact Info

Product

Resources

About